APA (7th ed.) Citation

Stahl, M., Roehmel, J., Eichinger, M., Doellinger, F., Naehrlich, L., Kopp, M., . . . Mall, M. (2022). WS17.02 Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged 2 through 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): A phase 2, open-label extension study. Journal of Cystic Fibrosis, 21, S32. https://doi.org/10.1016/S1569-1993(22)00250-8

Chicago Style (17th ed.) Citation

Stahl, M., et al. "WS17.02 Long-term Efficacy of Lumacaftor/ivacaftor (LUM/IVA) in Children Aged 2 Through 5 Years with Cystic Fibrosis (CF) Homozygous for the F508del-CFTR Mutation (F/F): A Phase 2, Open-label Extension Study." Journal of Cystic Fibrosis 21 (2022): S32. https://doi.org/10.1016/S1569-1993(22)00250-8.

MLA (9th ed.) Citation

Stahl, M., et al. "WS17.02 Long-term Efficacy of Lumacaftor/ivacaftor (LUM/IVA) in Children Aged 2 Through 5 Years with Cystic Fibrosis (CF) Homozygous for the F508del-CFTR Mutation (F/F): A Phase 2, Open-label Extension Study." Journal of Cystic Fibrosis, vol. 21, 2022, p. S32, https://doi.org/10.1016/S1569-1993(22)00250-8.